Treatment to Target Using Recombinant Interleukin‐1 Receptor Antagonist as First‐Line Monotherapy in New‐Onset Systemic Juvenile Idiopathic Arthritis: Results From a Five‐Year Follow‐Up Study
Top Cited Papers
Open Access
- 8 March 2019
- journal article
- research article
- Published by Wiley in Joint Bone Spine
- Vol. 71 (7), 1163-1173
- https://doi.org/10.1002/art.40865
Abstract
Objective Systemic juvenile idiopathic arthritis (JIA) is a multifactorial autoinflammatory disease with a historically poor prognosis. With current treatment regimens, approximately half of patients still experience active disease after 1 year of therapy. This study was undertaken to evaluate a treat‐to‐target approach using recombinant interleukin‐1 receptor antagonist (rIL‐1Ra; anakinra) as first‐line monotherapy to achieve early inactive disease and prevent damage. Methods In this single‐center, prospective study, patients with new‐onset systemic JIA with an unsatisfactory response to nonsteroidal antiinflammatory drugs received rIL‐1Ra monotherapy according to a treat‐to‐target strategy. Patients with an incomplete response to 2 mg/kg rIL‐1Ra subsequently received 4 mg/kg rIL‐1Ra or additional prednisolone, or switched to alternative therapy. For patients in whom inactive disease was achieved, rIL‐1Ra was tapered after 3 months and subsequently stopped. Results Forty‐two patients, including 12 who had no arthritis at disease onset, were followed up for a median of 5.8 years. The median time to achieve inactive disease was 33 days. At 1 year, 76% had inactive disease, and 52% had inactive disease while not receiving medication. High neutrophil counts at baseline and a complete response after 1 month of rIL‐1Ra were highly associated with inactive disease at 1 year. After 5 years of follow‐up, 96% of the patients included had inactive disease, and 75% had inactive disease while not receiving medication. Articular or extraarticular damage was reported in <5%, and only 33% of the patients received glucocorticoids. Treatment with rIL‐1Ra was equally effective in systemic JIA patients without arthritis at disease onset. Conclusion Treatment to target, starting with first‐line, short‐course monotherapy with rIL‐1Ra, is a highly efficacious strategy to induce and sustain inactive disease and to prevent disease‐ and glucocorticoid‐related damage in systemic JIA.Keywords
Funding Information
- FP7 Health (FP7/2007‐2013, EC‐GA No. 305266 ‘MIAMI’)
This publication has 40 references indexed in Scilit:
- Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in GermanyPediatric Rheumatology, 2018
- Juvenile idiopathic arthritis in adulthood: fulfilment of classification criteria for adult rheumatic diseases, long-term outcomes and predictors of inactive disease, functional status and damageRMD Open, 2016
- Application of the Yamaguchi criteria for classification of “suspected” systemic juvenile idiopathic arthritis (sJIA)Pediatric Rheumatology, 2012
- Consensus treatment plans for new‐onset systemic juvenile idiopathic arthritisArthritis Care & Research, 2012
- Systemic JIA: new developments in the understanding of the pathophysiology and therapyBest Practice & Research Clinical Rheumatology, 2009
- Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR).2007
- Predictors of disease course and remission in systemic juvenile idiopathic arthritis: Significance of early clinical and laboratory featuresArthritis & Rheumatism, 2006
- International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.2004
- Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcomeRheumatology, 2002
- Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort.2002